TYME earnings

Combined Company Will Operate as Syros Pharmaceuticals and Continue to Advance Syros' Ongoing Clinical Programs Syros Expects to Have Cash Into 2025; At Least a Year Past SELECT-MDS-1 Pivotal Data Now Planning to Initiate Phase 3 Clinical Trial of SY-2101 in APL 2H 2023 Syros to Host Conference Call at 8:30 AM ET Today Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, and TYME Technologies, Inc. (NASDAQ:TYME), today announced that the companies have entered into a definitive merger agreement pursuant to which Syros will acquire TYME, including its pipeline assets and net cash at closing which after accounting for wind-dow

– Georgetown University and associated Georgetown Medstar Centers continued enrollment in Phase II OASIS trial evaluating the potential benefits of oral SM-88 for patients with metastatic HR+/HER2- breast cancer after treatment with a CDK4/6 inhibitor – On track for mid-2022 full enrollment of HopES trial for SM-88 used in patients with high-risk Ewing's and other sarcoma types – Pursuing options to diversify the clinical pipeline – Well-capitalized position, with $92.0 million in cash and marketable securities as of December 31, 2021 – Company to host live conference call and webcast today, February 11, at 8:30 AM ET TYME Technologies, Inc. (NASDAQ:TYME) (the Company or TYME), an emer

TYME Technologies, Inc. (NASDAQ:TYME) (the "Company" or "TYME"), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announced that the Company will report its third quarter 2022 financial results on Friday, February 11, 2022, at 8:30 AM ET. Richie Cunningham, Chief Executive Officer, and Frank Porfido, Chief Financial Officer, will host a conference call and webcast as follows: Date: Friday, February 11, 2022 Time: 8:30 AM ET Toll-free (U.S.) (866) 601-3896 International (636) 812-6499 Conference ID 1286376 The webcast will be accessible on the Events & Presentations page of the Investors s

– First patient dosed in Phase II OASIS trial evaluating the potential benefits of oral SM-88 for patients with metastatic HR+/HER2- breast cancer after treatment with a CDK4/6 inhibitor – – PanCAN Precision Promise trial to add five new sites in early 2022 – – Commenced preclinical initiative with Evotec, a global leader in drug development, to evaluate the potential of expanding our SM-88 platform to other indications – – Maintained a well-capitalized position, with $96.6 million in cash and marketable securities as of September 30 – – Company to host live conference call and webcast today, November 8, 2021, at 8:30 AM ET – TYME Technologies, Inc. (NASDAQ:TYME) (the Company or TYME),

Company to report its second quarter fiscal 2022 financial results TYME Technologies, Inc. (NASDAQ:TYME) (the "Company" or "TYME"), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announced that the Company will report its second quarter 2022 financial results on Monday, November 8, 2021 at 8:30 AM ET. Richie Cunningham, Chief Executive Officer, and Frank Porfido, Chief Financial Officer, will host a conference call and webcast as follows: Date: Monday, November 8, 2021 Time: 8:30 AM ET Toll-free (U.S.) (866) 601-3896 International (636) 812-6499 Conference ID 5953454 The webcast will be accessible

– Completed strategic review, identifying breast cancer, second-line pancreatic cancer, high-risk sarcomas as priority clinical settings – - Announced OASIS breast cancer trial, a multicenter Phase II single-arm, open-label study of SM-88 used with methoxsalen, phenytoin, and sirolimus ("MPS") in metastatic HR+/HER2- breast cancer, with Georgetown University – - Granted U.S. patent claims covering use of tyrosine-based drug delivery method to treat cancer - –Appointed acting Chief Medical Officer Dr. Jan M. Van Tornout, and Chief Financial Officer, Frank Porfido - – Well-capitalized position, with $101.5 million in cash and marketable securities as of Q1 FY2022 - – Company to host liv

Company to report its first quarter fiscal 2022 financial results TYME Technologies, Inc. (NASDAQ:TYME) (the "Company" or "TYME"), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announced that the Company will report its first quarter 2022 financial results on Tuesday, August 10, 2021 at 8:30 AM ET. Richie Cunningham, Chief Executive Officer, and Frank Porfido, Chief Financial Officer, will host a conference call and webcast as follows: Date: Tuesday, August 10, 2021 Time: 8:30 AM ET Toll-free (U.S.) (866) 601-3896 International (636) 812-6499 Conference ID 4276767 The webcast will b